

Milestones

Building a Strong Future

Oct. 12, 2007

Filed registration for initial public offering

Oct. 2, 2007

Received FDA marketing clearance for Sleuth™ Implantable ECG Monitoring System, Transoma Medical's first commercially released clinical product

CONTACT INFORMATION

Brian Brockway
President and CEO

Charlie Coggin
Vice President and CFO

Nestor Jaramillo
Vice President of Sales and
Marketing, Patient Management
Device Division

Transoma Medical
4358 West Round Lake Road
St. Paul, Minnesota 55112
(651) 481-7444

Nancy A. Johnson / Nick Banovetz
Padilla Speer Beardsley
(612) 455-1745 / (612) 455-1705
njohnson@psbpr.com /
nbanovetz@psbpr.com

Company Overview

Transoma Medical, Inc., headquartered in St. Paul, Minn., is a medical technology company engaged in developing, manufacturing and distributing implantable, subcutaneous, wireless diagnostic and monitoring products. Transoma Medical is focused on two distinct markets - the chronic cardiovascular disease (CVD) market, through its Patient Management Device (PMD) division, and the biomedical research market, through its Data Sciences International (DSI) division.

The PMD division is furthering Transoma Medical's extensive technology platform by developing implantable wireless diagnostic systems that provide physicians with the patient diagnostic data to guide therapies and optimize treatments in CVD patients. These systems are designed to provide timely information, which may allow early detection of various abnormalities that, if untreated, could lead to hospitalization or possibly death.

Through its DSI division, Transoma Medical has become the leader in implantable wireless monitoring systems for biomedical research and has experienced 19 percent average annual growth for the past 11 years. DSI's innovative tools play a key role in drug discovery, preclinical evaluation of safety and efficacy, and other academic and government basic research. Customers turn to DSI for more accurate, timely physiological data; humane research practices; and faster times to market.

Transoma Medical has a strong intellectual property portfolio and technology platform. As of Oct. 1, 2007, Transoma Medical held 27 U.S. patents with 73 U.S. patent applications pending and 26 foreign granted patents with 18 foreign patent applications pending. The company has approximately 280 employees along with the infrastructure and proven executive management team to bring new products to the market.

Market Potential

Addressing Unmet Cardiovascular Diagnostic Needs

Cardiovascular disease is the number one cause of death in America today, according to the American Heart Association. An estimated 79 million American adults suffer from cardiovascular disease and approximately 2,400 die each day¹.

As more people live with cardiovascular conditions, such as cardiac arrhythmias, prompt and accurate diagnoses take on great importance. Abnormalities may be subtle or infrequent, and challenging to diagnose. Thorough, accurate cardiac data can assist physicians in prescribing optimal pharmaceutical therapy or implantable therapeutic devices.

The Sleuth™ Implantable ECG Monitoring System, the company's first commercially released clinical product, received Food and Drug Administration marketing clearance in October 2007. Sleuth is based on Transoma Medical's proprietary remote wireless technology, which has been widely used in biomedical research for more than two decades. The device helps detect cardiovascular conditions to assist physicians in providing a timely and relevant diagnosis.

Sleuth™ ECG Monitoring System

Detecting Difficult-to-Diagnose Arrhythmias

The Sleuth ECG Monitoring System is the first remote wireless implantable system available to capture long-term electrocardiogram (ECG) data for diagnosing cardiac arrhythmias. Arrhythmias can be serious and are often the root cause of unexplained syncope - a medical term for fainting. The Sleuth system offers an accurate, efficient way to monitor a patient's heart rate and rhythm 24/7. The wireless system records ECG data continuously and transmits reports to physicians in a timely manner to facilitate accurate diagnosis and optimal treatment.

Syncope Potentially Life Threatening

Syncope, or fainting, is characterized by a sudden and temporary loss of consciousness that typically occurs when blood pressure is too low, and the heart does not pump a normal supply of oxygen to the brain. Patients with syncope live in fear of not knowing when the next episode might occur. Left untreated, syncope can result in negative personal consequences, such as suspension of driving privileges or limited employment opportunities. Making an accurate diagnosis and providing prompt treatment is especially important for people who faint due to cardiovascular syncope. Those with an underlying cardiovascular cause have higher rates of sudden cardiac death². In the United States, syncope accounts for 3-5 percent of all emergency room visits and 1-6 percent of hospital admissions³, at an annual in-patient cost of approximately \$2.4 billion⁴.

A Need for Immediacy

Syncope caused by a cardiac condition can be especially challenging to diagnose because abnormal heart activity may be infrequent or not apparent to the patient. Conditions causing cardiovascular syncope include heart attack, congestive heart failure, obstructed blood flow and low blood pressure.

The Sleuth system continually monitors the heart's electrical activities and automatically transmits data from the patient's home to a monitoring center. The center analyzes the data and sends the resulting information directly to the physician's office.

Sleuth Monitors ECG Data and Detects Cardiac Event



ECG Data Transmitted via Base Station in Patient's Home



ECG Data Triaged at Monitoring Center



Physician Receives Report



Expanding the Clinical Product Portfolio

LVP-1000*

Transoma Medical is conducting two clinical studies to evaluate its LVP-1000 Left Ventricular Pressure Monitoring System, a device designed to assess heart failure patients. The LVP-1000 Monitoring System is an implantable wireless diagnostic device that remotely monitors and records left ventricular pressure, a parameter that many consider a highly specific, accurate indicator of the status of heart failure patients*.

* Limited to investigational use only. Not available for sale in the U.S.

Management Team

- Brian Brockway, President, CEO and Chairman
- Charlie Coggin, Vice President and CFO
- Vic Fabano, Vice President of Manufacturing Operations
- Jay Johnson, Vice President of Product Development
- Perry Mills, Vice President and Chief Technology Officer

Patient Management Device Division

- Dennis Crane, Vice President of Clinical Affairs
- Nestor Jaramillo, Vice President of Sales and Marketing
- Angela Raun, Vice President of Regulatory Affairs and Quality Assurance

References

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2007;115:e69-e171.
2. Olshansky B: Syncope: tailoring the diagnostic approach to fit the patient [Clinical Tutorials 9]. 20th Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology (NASPE), Toronto, Canada, 1999
3. Shen WK, Decker WW, Smars PA, et al. Syncope Evaluation in the Emergency Department Study (SEEDS): A Multidisciplinary Approach to Syncope Management. *Circulation* 2004;110:3636-3645.
4. Sun BC, Emond JA, Camargo CA. Direct medical costs of syncope-related hospitalizations in the United States. *The Am J of Cardiology* 2005;95:668-71.



003509-005 rev. 02